All In MedTech

Device Trial Radar · NCT06464107

Endometrial Cell Collection With the PadKit

Endometrial Cancer Cell Collection With the Preprogen PadKit™

Last checked: Nov 20, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

80

Actual

Start

May 31, 2024

Primary completion

Apr 17, 2026

Study completion Apr 17, 2026

Sponsor

Lead sponsor
Hackensack Meridian HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Preprogen
First posted
Jun 18, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Screening
FDA-regulated device
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

All patients will be provided with a Preprogen Pad to be worn for 4-6 hours to collect cells shed by the endometrium. After the kit is returned to the Preprogen laboratory, a brief survey will be completed. Analysis will be conducted to determine if the PadKit™ can collect a sample of endometrial cells sufficient to differentiate between normal and atypical hyperplasia/malignant cells in blinded samples provided to the laboratory for analysis.

Conditions

  • Neoplasms

Interventions

  • PadKit™ from PreprogenDevice

    The interlabial pad is classified as a Class 1 device by the FDA and the device is exempt from requiring a 510(k) approval. The interlabial pad is worn for 4-6 consecutive hours and collects cells shed from the cervix and uterine cavity. The pad is then removed and placed in the smaller, inner tube that contains the transport solution. After replacing the lid securely, it is then carefully placed back inside the larger outer tube with the outer lid secured and returned to the original box. The entire box is placed in the polybag and mailed back to the lab for analysis.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Observation of the presence of endometrial cells captured by the pad.Time frame: Within 7 days after receipt of the pad from patients
  2. Association of the presence/absence of cells and morphologyTime frame: Within 7 days after receipt of the pad from patients

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Jersey Shore University Medical Center

    Neptune City, New Jersey

  • Riverview Medical Center

    Red Bank, New Jersey

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.